The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

Causality remains to be established in every patient against naturally-occurring TB, particularly in countries with high TB indidence rates

Publications

Lau KS, Cheung BM, Lam KO, Chan SY, Lam KM, Yeung CF, Hung IF, Kwong DL, Tong CC, Leung TW, Luk MY, Lee AW, Yuen KK, Lee VH

Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report.

BMC infectious diseases 2021 Nov 10;21;1148 — 2021 Nov 10 — 1148

Roussel L, Brindel A, Pouget C, Treffel G, Billon Y, Vaillant P, Tiotiu A

Pleural Effusion Occurring During Lung Cancer Immunotherapy: A Challenge for the Clinician.

Archivos de bronconeumologia 2021 Jun 04;; — 2021 Jun 04

Murakami S, Usui R, Nakahara Y, Kondo T, Kato T, Saito H

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy.

Internal medicine (Tokyo, Japan) 2020 Dec 29;; — 2020 Dec 29

He W, Zhang X, Li W, Kong C, Wang Y, Zhu L, Xu R, Deng G, Zhang P

Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report.

OncoTargets and therapy 2018;11;7423-7427 — 2018 — 7423-7427

Elkington PT, Bateman AC, Thomas GJ, Ottensmeier CH

Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.

American journal of respiratory and critical care medicine 2018 Dec 01;198;1451-1453 — 2018 Dec 01 — 1451-1453